Key result
Malvidin protects against doxorubicin-induced cardiotoxicity in preclinical rat models.
Key points are not available for this paper at this time.
Population
Experimental rat models
Design
Animal experimental study
Background: Malvidin (MAL) is an anthocyanidin having therapeutic characteristics that provide several therapeutic advantages. Doxorubicin (DOX) is a valuable anti-tumor drug with a wider anticancer range; nevertheless, DOX
No takes yet. Share an insight, caveat, or question.
Mi et al. (2025) studied this question. Malvidin demonstrated cardio-protective effects against doxorubicin-induced cardiotoxicity in experimental rat models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: